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E fforts to investigate a polysaccharide-based group B Neisseria meningitidis (GBM) vaccine have been hampered for 2 main reasons: the poor immunogenicity of the capsular polysaccharide alone 1 and concerns about potential autoimmunity induced by antibodies toward the capsular polysaccharide, polymers of ␣(238) linked N-acetylneuraminic acids (PSA), present in the GBM capsule that is structurally identical to PSA present on neural cell adhesion molecules (PSA-NCAM) in fetal and adult mammalian neural tissues. [2] [3] [4] [5] After birth, the relatively long chains of PSA on NCAM (Ͼ12 residues), which are more reactive with PSA antibodies than shorter chains, become progressively shorter in most human tissues, except in certain brain tissues and on natural killer cells, presumably changing their NCAM-function from a plasticity promoting to a more stability promoting molecule. 4,6 -11 Convalescent patients from GBM disease have increased concentrations of immunoglobulin M and immunoglobulin G PSA antibodies. 12, 13 Immunoglobulin G, but not immunoglobulin M crosses the placenta. 14 Devi et al 15 have reported equal or higher PSA antibody levels in the umbilical cord than in the corresponding maternal sera. PSA antibodies are common in the general population, likely arising from intestinal carriage of Escherichia coli K1, asymptomatic pharyngeal carriage of non pathogenic GBM, or exposure to Moraxella nonliquefaciens, all expressing capsular PSA. 13, 16 Because group C N. meningitidis (GCM) capsular polysaccharide, polymers of ␣(239) linked N-acetylneuraminic acids, differs from GBM capsular polysaccharide by only 1 linkage, convalescent patients from GCM disease can serve as a control group in addition to the background population. 13 The capsular polysaccharides of GBM and GCM do not cross-react immunologically. 17 In a Danish national cohort study, we found that subjects convalescent from GBM disease had no increased risk of autoimmune diseases up to 31 years after their acute episode of meningococcal disease compared to persons with a history of GCM disease or persons without a history of meningococcal disease. 18 We formed the following null hypotheses to explore whether GBM disease induces an immunologic reaction in the fetus:
Women convalescent from GBM disease have the same risk of preterm delivery, giving birth to stillborn infants or infants small for the gestational age as women with a history of GCM disease or women with no history of meningococcal disease, and children born to women with a history of GBM disease have the same risk of birth defects and/or diseases within the first 3 years of life as children born to women with a history of GCM disease or women with no history of meningococcal disease.
MATERIALS AND METHODS
The study was based on 4 national registries: The Danish Civil Registration System, the Registry of Communicable Diseases, the Hospital Discharge Registry and the National Registry of Abortions. The study was approved by the Danish Data Protection Agency and person-related information was stored and treated in accordance with regulations. Thus, no informed patient consent was required.
The Danish Civil Registration System. Since April 2, 1968, The Civil Registration System has assigned an identification number to all persons living in Denmark. The registry holds information on date of birth, immigration/emigration, death, and identification of parents and children. 19 The Registry of Communicable Diseases. Since 1980, it has been mandatory for clinicians to report specified cases of communicable diseases, including meningococcal disease, to the Department of Epidemiology at the Statens Serum Institut. 20 In addition, the Neisseria and Streptococcus reference laboratory, also at Statens Serum Institut, has received meningococcal disease isolates for serogrouping from the local Departments of Clinical Microbiology since 1974. 21 Copies of laboratory results have since 1992 been sent concurrently to the Department of Epidemiology and a notification form was requested if not received. 21, 22 In a capture-recapture analysis, the completeness of the database from 1994 to 2002 has been estimated to be above 95%. 23, 24 The completeness of the notifications for meningococcal disease in the period 1974 -1992 in Denmark is estimated to be high because of the severity of the disease and because monitoring of invasive meningococcal strains by serogroup, only done at Statens Serum Institut, was considered important, owing to the availability of the polysaccharide group A and C meningococcal vaccines from the beginning of the 1970s. 18, 21 We used data from the entire period 1974 -2005 for this study. 18 The Hospital Discharge Registry. The hospital discharge registry has recorded all diagnoses of hospital discharges in Denmark, including diagnoses from obstetric and pediatric departments. Birth defects have been registered centrally since 1963 but computerized only since 1973. Birth defects have been recorded concurrently in 3 independent registries: the National Registry of Congenital Abnormalities (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) , 25 the Medical Birth Registry (1973-present), 26 and the Hospital Discharge Registry (1977-present). 27 Larsen et al 28 compared the 3 registries for birth defects in the period 1991-94. The Hospital Discharge Registry had a predictive value of birth defects of 88.2% (95% confidence interval (CI): 85.9 -90.5%) and completeness of 89.9% (95% CI: 87.7-92.1%), which they concluded was acceptable for general surveillance and epidemiologic research regarding birth defects. The completeness of the Hospital Discharge Registry on birth defects for the period 1977-1991 has to our knowledge not been accessed, but we consider the risk for differential misclassification small, because a history of meningococcal disease in the mother is not an established risk factor for birth defects in the offspring. The 2 other registries had higher predictive values, but their completeness was calculated to be below 40%. We decided to use data from the Hospital Discharge Registry for the period 1977-2005.
Birth defects have the following codes in the eighth revision of the International Classification of Diseases (ICD-8) 740.00 -759.99 and in ICD-10 Q00.0 -Q99.9. We excluded the following diagnoses (ICD-8; ICD-10): patent ductus arteriosus (747.07; Q25.0), undescended testis (752.10 -752.19; Q53.00 -Q53.99) and hip dislocation (755.60 -755.69; Q65.00 -Q65.99) because the diagnostic criteria are expected to vary among both hospital physicians and midwives. 28, 29 The 10 organ-specific subgroups of birth defects are adapted from the ICD-8 and ICD-10 classification system.
In the analyses we assessed the following outcomes in the period 1974 -2005: stillbirth (death after gestational week 28), preterm birth (Ͻ37 weeks of gestation), low birth weight (Ͻ2500 g), and low birth weight for the gestational age at delivery, defined as weight below the 10th percentile at the respective gestational age for Danish newborns.
Data Analysis. The study was designed as 2 dependent cohort studies. Date of hospital admission or of out-patient contact to the hospital was used for both cohorts as "outcome variables." Only primary and secondary ICD-8 and ICD-10 discharge diagnoses have been included.
Cohort I included females with either a registered GBM or a GCM disease in the period 1974 -2005 and a reference group consisting of all Danish females with no record of meningococcal disease. Case definitions are described elsewhere. 18 The cohort was followed until first child delivery, registered pregnancy complication, or the end of the follow-up period, whichever came first. In the analyses, we adjusted for age, calendar period (1977-1979, 1980 -1984, 1985-1989, 1990 -1994, 1995-1999, and 2000 -2004) , and county of residence at child delivery, and when the pregnancy resulted in a vital infant we adjusted for the sex of the infant. No interaction terms were found to significantly alter the results and thus omitted.
Only the outcome of the first pregnancy was included in the logistic regression analysis because we would expect dependency between pregnancy outcomes. The following binary outcomes were assessed: stillbirth, delivery before gestational week 37, infant weight at delivery below 2500 g, and low birth weight for the gestational age.
Cohort II included all children born to women with a recorded GBM or GCM disease from cohort I. For every child within this cohort, we selected up to 10 children as controls from the general population, with no record of meningococcal disease among their mothers. The children were matched according to sex, date of birth (Ϯ10 days), mother's age, gestational age, birth weight (in subgroups of 250 g), county of birth, and number of older siblings.
In the logistic regression analysis, we calculated the odds ratio (OR) of first registered birth defects of children, at any time after birth overall and for each ICD-subgroup. To adjust for any increased risk among children born of women with an underlying disease, we included the comorbidity index for the children's mothers.
Furthermore, we used proportional hazards regression to calculate the hazard ratio of hospital-diagnosed diseases within the first 3 years of life. In the overall analyses for birth defects and diseases within the first 3 years of life, subjects were censored at the first incident, despite diagnostic subgroup. When repeating the analyses in subgroups, the subjects were censored at the first incident in each subgroup. This explains why the sum of outcomes in the subgroups may add up to more than the overall number sum of outcomes. Comorbidity Index. For all females in cohort I and mothers of the corresponding children in cohort II, we adjusted for coexisting severe illnesses by a comorbidity index, first described by Charlson et al. 30 In our index we defined 32 different ICD-8 and the comparable ICD-10 diagnostic groups and calculated the relative mortality, which served as weights in these survival analyses. The sum of the log transformed weights formed the comorbidity index and thereby we were able to adjust for differences in comorbidity between individuals with a previous GBM or GCM disease and the background population in the analyses.
those with previous GBM disease, there were 227 registered live childbirths and 1 stillbirth as the first pregnancy outcome; 12 were delivered preterm. This compares to 86 live childbirths and 1 stillbirth among women with a previous GCM disease; there were 4 preterm deliveries. Overall, we found no increased risk of stillbirth or preterm delivery for women with a previous GBM disease relative to the general population or to those with GCM disease (Table 1) . Likewise, we found that infants born to women with a GBM disease were not small for gestational age at delivery (OR adjusted : 0.64; 95% CI: 0.39 -1.04) ( Table 1) . Birth Defects. Cohort II included 502 children born to mothers with a previous GBM disease, 208 children born to mothers with a previous GCM disease and 6394 individually matched referents from the general population; 4567 referents for the children born to mothers with a history of GBM disease and 1827 referents for the children born to mothers with a history of GCM disease.
Among the 502 children born to women with a previous GBM disease, we identified 41 children with birth defects (Table 2 , http://links.lww.com/A615). The comorbidity adjusted odds ratio was 1.14 (95% CI: 0.80 -1.62) compared to the matched controls and 1.00 (95% CI: 0.53-1.90) compared to children born to mothers with a previous GCM disease. Birth defects in the urinary tract system were more frequent among children born to mothers with a previous GBM disease, OR comorbidity adjusted 6.27 (95% CI: 2.03-19.38) but not compared to children born to mothers with a previous GCM disease, OR comorbidity adjusted 1.13 (95% CI: 0.07-19.02). The 6 birth defects among children born to mothers with a GBM disease were (ICD-8/ICD-10): congenital renal cysts (753.19), polycystic kidney, unspecified (Q61.3), congenital hydronephrosis (3 subjects, Q62.0), and accessory kidney (Q63.0). Congenital hydronephrosis was the only diagnosis occurring more than once and compared with 6 children of the background population, OR comorbidity adjusted 3.62 (95% CI: 0.86 -15.17), and 2 children born by mothers with a previous GCM disease, OR comorbidity adjusted 0.71 (95% CI: 0.03-16.76). We found 2 subjects with nervous system birth defects among children of mothers with previous GBM disease (ICD-10): microcephaly (Q02.9) and congenital hydrocephalus, unspecified (Q03.9). This was not significantly higher than in the general population. Diseases Among 0-to 2-Year-Olds. Overall, there was no increased risk of diseases within the first 3 years of life for children born to women with a previous GBM disease (HR comorbidity adjusted : 0.94; 95% CI: 0.79 -1.12). Likewise, the children had no increased risk of dying within the first 3 years of life compared to the general population (HR comorbidity adjusted : 0.90; 95% CI: 0.25-3.26) (Table 3, http://links.lww.com/A615).
The subgroup analyses showed an excess risk of diseases in blood and/or blood-forming organs within the first 3 years of life (HR comorbidity adjusted : 3.89; 95% CI: 1.11-13.63). The results were based on 5 cases only, which were (ICD-8/ICD-10): iron deficiency anemia (280.09); hemorrhagic thrombocythemia (287.29); hereditary factor VIII deficiency (2 subjects, D66.9) and nutritional anemia, unspecified (D53.9). No cases were registered in this subgroup among children born to mothers with a history of GCM disease (Table 3 , http://links.lww.com/A615).
We found no increased risk of neurodevelopmental disorders within the first 3 years of life. Differences between the groups for mental and behavioral disorders (HR comorbidity adjusted : 0.53; 95% CI: 0.14 -1.96), and diseases of the nervous system (HR comorbidity adjusted : 1.07; 95% CI: 0.45-2.53), were insignificant (Table 3 , http://links.lww. com/A615).
DISCUSSION
We studied women with previous GBM disease to clarify if they had increased risk of late pregnancy complications and/or their biologic children had increased risk of adverse birth outcomes. Overall, we did not find an association between females' previous GBM disease and stillbirths, preterm delivery, birth of infants small for the gestational age, and birth defects or diseases in the children's first 3 years of life. 
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Meningococci and Birth Defects GBM and GCM convalescents were compared with the entire Danish population of women with no history of meningococcal disease. Because meningococcal disease involves either systemic or CNS inflammation, a high proportion of survivors (11-19%) have sequelae, and more so when neurodevelopmental outcomes are considered (ie, learning difficulties and social problems). [31] [32] [33] [34] [35] [36] [37] GCM is second to GBM in the developed world as disease-causing N. meningitidis serogroups. 38 Few countries have health registries that allow longitudinal follow-up and comparison of women with respect to pregnancy delivery outcomes and complications in their offspring where information is collected independently of the study questions. However, the study design has some limitations because we relied on recorded data (ie, the inability to ask for specific detailed information, like waiting time to pregnancy, number of spontaneous abortions, and milder childhood diseases that do not demand hospitalization). In addition, disease coding has changed over time and only limited quality control of the registered codes has been conducted for the various outcomes. The results, however, are adjusted for calendar time with regard to the pregnancy outcomes and matched for the analyses of birth defects and diseases within the first 3 years of life. 27 It is likely that women with a history of a severe meningococcal disease are more prone to hospitalization afterward than is the background population. However, such a differential misclassification would only overestimate the burden of disease/complication in the study group compared to the background population, and we do not expect persons with a GBM disease to differentiate from women with a history of GCM disease. In addition, the median time between meningococcal disease and pregnancy outcomes and birth defects was Ͼ10 years, which minimizes risk of diagnostic dependency between exposure and outcome events.
The registered data on abortions were limited to induced abortions for the period 1977-2005 and spontaneous abortions at hospitals since 1995. In the initial analyses, we studied abortions as an outcome but did not find an association with persons with a history of GBM disease. Thus, we have refrained from reporting results on abortions for 2 reasons: first, a reason for an induced abortion may have other explanatory factors, like social or diseaserelated causes and because we do not have this information, we are unable to control for it and may risk reporting a biased result. Second, information on spontaneous abortions are sparse, only to be reported from hospitals since 1995. Because most abortions are spontaneous and occur outside hospitals setting and probably often without the women knowing it, we are left without the number of pregnancies in Denmark. Accordingly, we could not assess any association of neuromalformations, which might occur in the first trimester when the central nervous system and most organs are initiated. However, according to our study, if neuromalformations do occur without inducing an abortion, they are not associated with preterm delivery, giving birth to an infant small for gestational age, birth defects in offspring, or diseases within the first 3 years of life according to our study.
Because advanced screening programs of pregnant women have only been instituted recently in Denmark, any subsequent decrease in birth defects should have little impact on the 2 cohorts covering 28 years each.
With the exception of the group of urinary tract defects, we found no increased risk of birth defects in children born to women with a history of GBM disease compared to the general reference population. Within the group of birth defects of the urinary system only congenital hydronephrosis was registered in more than 1 subject in each of the 3 exposure groups; the diagnosis was not made significantly more often in children born to mothers with a history of GBM disease compared to the reference populations.
We demonstrated previously that persons with a history of GBM disease are at no increased risk of autoimmune diseases for up to 31 years after meningococcal disease. 18 If PSA antibodies react as autoantibodies, binding to PSA-NCAM expressed particularly in the fetal tissue, we would have expected the persons with a history of GBM disease to be at increased risk of autoimmune diseases and in particular, the fetuses of the exposed mothers to be vulnerable to pregnancy complications and birth defects.
The lack of information on pre-and early pregnancy complications, including waiting time to pregnancy and spontaneous abortions preclude conclusions for the early pregnancy period. However, for the period around delivery and the first 3 years of life, our data indicate no statistically significant associations between previous GBM disease and developmental abnormalities during ontogenesis which persist until birth. These results are consistent with our findings that persons with a history of GBM disease have no increased risk of autoimmune diseases later in life.
